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The aim of this study was to evaluate the clinical efficacy as determined by time to progression and response rate (RR) of autologous
vitespen (formerly HSPPC-96; Oncophage, Antigenics Inc., New York, NY, USA) with and without interleukin-2 (IL-2; Proleukin:
Chiron, Emoryville, CA, USA) in stage IV metastatic renal cell carcinoma (RCC) patients undergoing nephrectomy. Eighty-four
patients were enrolled on study, and then underwent nephrectomy and harvest of tumour tissue for use in autologous vaccine
manufacture. Initial treatment schedule started approximately 4 weeks after surgery and consisted of six injections: once weekly for 4
weeks, then two injections biweekly (vaccines administered at weeks 1, 2, 3, 4, 6, 8), followed by restaging at or around week 10.
Patients who had stable or responsive disease continued to receive vaccine, with four more vaccinations biweekly (at weeks 10, 12,
14, 16). Patients who had progressive disease at week-10 evaluation received four consecutive 5-day-per-week courses of
11 10
6U of IL-2 subcutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at 2-week intervals (at weeks 10, 12, 14, 16). At
the next evaluation (week 18), patients with a complete response received two further cycles of vitespen (with IL-2 if also received
during prior cycle) or until vaccine supply was exhausted. Patients with stable disease or partial response repeated their prior cycle of
therapy. Disease progressors who had not yet received IL-2 began IL-2 treatment, and progressors who had already received IL-2
came off study. Of 60 evaluable patients, 2 demonstrated complete response (CR), 2 showed partial response (PR), 7 showed stable
disease, and 33 patients progressed. Sixteen patients had unconfirmed stable disease. Two patients who progressed on vaccine alone
experienced disease stabilisation when IL-2 was added. Treatment with vitespen did not result in a discernable benefit in the majority
of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of
vitespen.
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Metastatic renal cell carcinoma (RCC) has a poor prognosis, with a
reported median survival of approximately 1 year (Motzer et al,
1999). Evidence that clear-cell RCC is an immunogenic tumour
includes observed spontaneous tumour regression in 1–4% of
patients (Elhilali et al, 2000), the presence of lymphocytic
infiltrates in tumour, and responsiveness of RCC to cytokine
therapy. A number of studies have been reported demonstrating
the ability of interferon alpha and interleukin-2 (IL-2) to engender
a tumour response (Fyfe et al, 1995; Pyrhonen et al, 1999; MRCRC
Collaborators, 1999; Yang et al, 2003b; McDermott et al, 2005).
High-dose IL-2 has consistently resulted in complete responses in
4–8% of patients, with durable responses in the majority of these
individuals (Fyfe et al, 1995; Yang et al, 2003a; McDermott et al,
2005). In the case of interferon, two randomised studies
demonstrated a modest survival advantage for those who received
the agent (MRCRC Collaborators, 1999; Pyrhonen et al, 1999). A
recent study demonstrated equal efficacy for standard and low
dose interferon therapy (Tannir et al, 2006). Nevertheless, both
interferon alpha and IL-2 are toxic, and the large majority of
individuals who receive them derive no benefit. Efforts to develop
more sophisticated immunotherapy platforms for this disease,
including newer cytokine therapy (Alatrash et al, 2004), vaccine
therapy (Uemura et al, 2006; Ernstoff et al, 2007), and
nonmyeloablative transplantation (Childs et al, 2000; Artz et al,
2004; Rini et al, 2006), have been reported. Although these
approaches have demonstrated tantalising indications of efficacy
in a small group of individuals, they have not reached the
threshold of therapeutic efficacy or safety.
Heat shock proteins (HSPs) are intra- and extracellular
chaperones associated with stress response (Udono et al, 1994).
Exogenous antigens chaperoned by a HSP can be channelled into
the endogenous pathway, presented by MHC class I molecules, and
recognised by CD8þ T lymphocytes (Suto and Srivastava, 1995).
This process has been called cross-priming, and facilitates the
recognition of tumour antigens if administered as an exogenous
protein (Suto and Srivastava, 1995; Binder et al, 2001). Vitespen
(formerly HSPPC-96; Oncophage; Antigenics, New York, NY, USA)
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sis an autologous, tumour-derived HSP gp96-peptide complex that
possesses potent-specific antitumour activity in melanoma and
colon cancer xenograft models (Rivoltini et al, 2003), and
demonstrated promising preliminary results in a phase I trial in
colon cancer patients (Mazzaferro et al, 2003). Patients undergo
tumour harvest, and vitespen is extracted, processed and
administered as an injectable agent.
Owing to the documented response of RCC to immune therapy,
it was considered an ideal disease for further investigation of
vitespen. This paper is the first to present phase 2 data on patients
with metastatic RCC receiving vitespen.
PATIENTS AND METHODS
Patients
Eligible patients had primary-intact renal tumour with bidimen-
sionally measurable metastatic disease, and were scheduled to
undergo nephrectomy at MD Anderson Cancer Center (MDACC).
Eligibility criteria included the following: (1) pathological con-
firmation of RCC diagnosis; (2) X9g of non-necrotic, resectable
primary RCC for vaccine preparation; (3) life expectancy of X16
weeks; (4) Zubrod performance score of o2; (5) age of X16 years;
(6) normal white blood cell and platelet counts; (7) bilirubin
o1.5mg percent, AST o4 times the upper limit of normal, and
serum creatinine of o2mg percent.
All patients underwent clinical and radiographic staging before
treatment. Patients were excluded from the study if they had
received prior chemotherapy or immunotherapy; had active brain
metastases, serious intercurrent medical illness requiring hospita-
lisation, history of primary or secondary immunodeficiency; were
taking immunosuppressive drugs; were pregnant or lactating; or
were on an intercurrent clinical trial. All patients gave written
informed consent to participate in the study. The clinical protocol
was approved by the Institutional Review Board of The University
of Texas MD Anderson Cancer Center.
The study’s primary efficacy end points were the rate of
complete and partial response, the rate of secondary complete and
partial response (after IL-2), and time to progression (TTP).
Overall survival was also captured and recorded. Secondary end
points included safety of vitespen treatment.
As of 6 July 1999, eligibility criteria were altered to include
patients with a life expectancy of X12 weeks. Patients with prior
chemotherapy, immunotherapy, or radiotherapy were eligible but
had to be fully recovered from prior therapy. Initial accrual of 60
patients was planned and subsequently increased to 79, with 84
patients ultimately enrolling at a single centre (MDACC).
Vaccine preparation and administration
Patients underwent cytoreductive nephrectomy at MDACC. At
least 9g of fresh, non-necrotic tumour was acquired at the time of
surgery and 3g for immunological assays. Samples were placed
into sterile vials, packed in dry ice, and shipped to Antigenics. At
the Antigenics facility, tumour specimen was homogenised and
centrifuged, and the resultant supernatant precipitated using
ammonium persulphate. The resulting precipitate was then passed
through sequential Sephacel columns, and the fractions containing
vitespen were pooled, filtered, and stored at  801C. Testing to
assure product quality included sterility and endotoxin testing,
and then aliquots were released to the MDACC research pharmacy
for administration.
Initial treatment schedule started approximately 4 weeks after
surgery and consisted of six injections: once weekly for 4 weeks,
then two injections biweekly (vaccines administered at weeks 1, 2,
3, 4, 6, 8), followed by restaging at or around week 10. Patients who
had stable or responsive disease continued to receive vaccine, with
four more vaccinations biweekly (at weeks 10, 12, 14, 16). Patients
who had progressive disease at week-10 evaluation received four
consecutive 5-day-per-week courses of 11 10
6U of IL-2 sub-
cutaneously (weeks 10, 11, 12, 13), with four doses of vitespen at
2-week intervals (at weeks 10, 12, 14, 16). At the next evaluation
(week 18), patients with a complete response received two further
cycles of vitespen (with IL-2 if also received during prior cycle) or
until vaccine supply was exhausted. Patients with stable disease or
partial response repeated their prior cycle of therapy. Disease
progressors who had not yet received IL-2 began IL-2 treatment,
and progressors who had already received IL-2 came off study.
Response assessment
Lesions, measuring 41.0cm, were considered measurable. Any
lesion measuring p1.0cm was considered evaluable but not
measurable. Bone lesions were considered measurable only if a
measurable soft tissue component were present.
Complete response was defined as the disappearance of tumour
for X8 weeks. Partial response was defined as a X50% decrease in
the sum of the products of diameters of all measured lesions
persisting for X8 weeks, with no increase in size of lesion or
appearance of new lesions. Minor response was defined as a
decrease in the sum of the products of diameters of X25% and
o50% for X8 weeks. Stable disease was defined as o25% growth
or shrinkage for X8 weeks. Progressive disease was defined as an
increase of 25% in the sum of the products of diameters of any
measurable lesion, or in estimated size of a nonmeasurable lesion
or appearance of an unequivocal new lesion.
All radiological imaging evaluations performed on patients in
this study were reviewed by an external independent radiologist
for confirmation of data acquired from the study.
Statistical considerations and methods
A patient was considered enrolled if the patient signed the
informed consent form and met all eligibility criteria. An enrolled
patient was considered treated if the patient received X1 vitespen
vaccine. A treated patient was considered evaluable for response
assessment if the patient had a baseline visit and completed at least
one post-treatment tumour assessment, or had a documented
clinical progression in the absence of tumour assessment. All
evaluable patients were included to assess primary efficacy. All
treated patients were included to assess safety and secondary
efficacy (overall survival).
In general, continuous variables were summarised as mean, s.d.,
median, minimum, and maximum. Categorical variables were
summarised as the number and percentage of patients in each
category. Time-to-event data were analysed using the product limit
method (Kaplan–Meier estimate). All statistical analyses were
performed using SAS
s, version 8.2.
RESULTS
Between July 1999 and March 2000, 84 patients were enrolled into
the study. Of these, 60 were considered evaluable for response.
Reasons for inevaluability included protocol ineligibility (n¼12)
and failure to receive vaccine (n¼12). Of those who failed to
receive vaccine, two were unresectable, one had no viable tumour
tissue for vaccine production, three had non-RCC histology, and
six died before receiving vaccine. Of these, two patients could not
be weaned off the respirator post-nephrectomy. Two patients
developed progressive brain metastases in the immediate post-
operative period. Two patients had rapid progression of disease
prior to nephrectomy and did not undergo surgery. Patient
characteristics are outlined in Table 1.
Vaccination of metastatic RCC patients
E Jonasch et al
1337
British Journal of Cancer (2008) 98(8), 1336–1341 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMedian time from enrollment to nephrectomy was 5.5 days
(min–max 0–34 days), and median time from enrollment to first
vaccine was 38 days (min–max 27–65 days).
Of the 60 evaluable patients, 39 patients had demonstrated clear
progression by the time of first evaluation, and five patients
demonstrated stable disease. Of the three patients who
demonstrated partial response, two went on to show a complete
response. Both complete responders demonstrated some degree of
spontaneous tumour shrinkage postnephrectomy at baseline. The overall
median TTP from the first vaccine administration of the vitespen
only phase of the trial was 65 days (95% confidence interval (CI),
62.0–88.0 days) (Table 2a). By univariate analysis, performance
status, tumour histology (conventional vs non-conventional),
Memorial Sloan Kettering Cancer Center (MSKCC) risk factors,
or number of metastatic sites did not impact RR or TTP (Table 3).
A total of 23 patients received vaccine plus IL-2 at the time of
first progression. Of these patients, one demonstrated a PR and
five had stable disease at the time of next evaluation. Overall TTP
for this group was 168 days from the time of first treatment
(including time on vitespen alone) (95% CI 122–233 days)
(Table 2a).
Median survival for all patients was 476 days (95% CI 249–691
days) (Table 2b). Survival was significantly impacted by the
number of prognostic risk factors (P¼0.017). Patients with 0 risk
factors had a median survival of 779 days (95% CI 387–1338 days),
whereas those with more than one risk factor had a survival of only
330 days (95% CI 153–525 days) (Figure 1).
Vitespen was not associated with frequent side effects. Only
three patients experienced any treatment-related adverse events,
and only one had any reported serious treatment-related side
effects. The first patient reported some soreness at the injection
site, and the second showed some flushing after vaccine
administration. The patient who experienced reported serious
treatment-related side effects was a 55-year-old male with RCC and
metastases to the bone and lung. Immediately before his first
vaccine, the patient had an elevated WBC count of 14.4. One, two,
Table 2a Response evaluation according to treatment
Overall HSPCC alone HSPCC+IL-2
Response rate N¼60 (%) N¼59 (%) N¼23 (%)
CR 2 (3.3) 2 (3.4) 0
PR 2 (3.3) 1 (1.7) 1 (4.3)
SD 7 (11.7) 5 (8.5) 5 (21.7)
PD 33 (55.0) 39 (66.1) 14 (60.9)
Unconfirmed stable
disease
16 (26.7) 12 (20.3) 3 (13.0)
TTP from first treatment
in days
65 (95% CI
63.0–88.0)
65 (95% CI
62.0–88.0)
168.0 (95% CI
122.0–233.0)
Table 3 Response according to patient characteristics
Parameter
Median time to
progression (days)
95% Confidence
interval
Performance status
0 65.0 (61.0–91.0)
1 or greater 70.0 (63.0–118.0) (NS)
MSKCC risk factors
0 69.0 (63.0–118.0)
2 or greater 64.0 (61.0–77.0) (NS)
Tumour histology
Conventional 69.0 (62.0–91.0)
Nonconventional or
sarcomatoid
64.0 (62.0–93.0) (NS)
Number of metastatic sites
Single 76.0 (60.0–117.0)
Multiple 65.0 (62.0–91.0) (NS)
Table 1 Patient characteristics
Variable N¼60 (%)
Median age in years (range) 57.0 (39.0–79.0)
Gender
Male 47 (78)
Female 13 (22)
Zubrod performance status
0 31 (52)
1 19 (32)
2 8 (13)
Missing PS 2 (3)
Tumour pathology
Conventional grade II 10
Grade III 23
Grade IV 15
Sarcomatoid features 7
Other 5
No. of disease sites
11 8
22 8
31 3
42
MSKCC risk groups
02 5
1–2 30
3 or greater 2
Missing data 3
Table 2b Overall survival
Overall HSPCC Alone HSPCC + IL-2
N 72 35 37
Survival from first
treatment in days
476 (95% CI
249.0–691.0)
584 (95% CI
123.0–1026.0)
476 (95% CI
330.0–691.0)
MSKCC criteria 0 >1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Time to death (days)
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Figure 1 Overall survival by risk factors.
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sand three weeks later, the total WBC count had increased to 19.5,
18.1, and 30.6, respectively. One month after initiating treatment,
the patient was seen in the clinic for fever, cough, and increasing
shortness of breath, thought to be clinical signs of pneumonia. The
patient reported that his fever and arthralgia seemed to occur
during the period immediately following vaccine administration.
The patient’s symptoms also included somnolence, decreased
urinary output and diffuse aches lasting up to 48h after each
vaccine injection. He was admitted to the hospital and a chest
X-ray and blood cultures were obtained. Antibiotics (i.v.) were
initiated. Chest X-ray showed a metastatic lesion and possible early
pneumonia. CT scan of the brain showed no definite lesions. The
investigator reported that he felt the patient experienced a
paraneoplastic syndrome. The event was described as a leukemoid
reaction with predominant eosinophilia, citing as a possible
mechanism cytokine stimulation resulting in anuria, capillary leak
syndrome, and oliguria. The patient’s condition continued to
deteriorate until he died in the hospital.
No responses were seen in patients with non-conventional
histology, although one patient with conventional histology and a
sarcomatoid component had a complete response. No association
between Fuhrman nuclear grade and response was seen in patients
with conventional RCC; one complete responder had Fuhrman
nuclear grade II conventional type RCC, and the second complete
responder had conventional type RCC with sarcomatoid dedifferentia-
tion (Table 3).
Specific evaluation of those complete responders demonstrated
three common features: good baseline performance status, lung
only metastases, and some degree of spontaneous tumour
regression post-nephrectomy. Both of these patients are in
continuous complete remission over 7 years since the start of
vitespen (Tables 4a and b).
DISCUSSION
Vaccine therapy has demonstrated promise in preclinical cancer
models, although this promise has yet to translate into consistent
clinical efficacy. The reasons for the failure to achieve clinical
efficacy with vaccine therapy are unclear but a number of potential
roadblocks exist. Common problems include the inability to
engender antitumour immunity, which may due to tumour-
induced anergy. Anergy may be induced directly through
interaction of tumour cells with immune cells, or indirectly via
production of humoral factors by tumours that locally block
cytotoxicity, or via systemic factors, including vascular endothelial
growth factor. Other difficulties include failure of effector cells to
compete with growing tumour burden; antigen/MHC loss; and
T-cell dysfunction or production of suppressor T cells, including
regulatory T-cells. To optimise immunotherapy, correction of
immune-deactivating signals and attenuation of inhibitory factors
are likely necessary.
One of the specific impediments to engendering an immune
response in cancer is the failure of exogenous antigen to induce a
type I immune response. At the cellular level, priming of dendritic
cells with exogenous antigen typically induces an MHC class II-
mediated effect. Because CD8 cytotoxic T cells are thought to play
a pivotal role in achieving immune-mediated tumour destruction,
cross-presentation of exogenous antigen to the MHC class I
pathway is an important event. Cross-presentation is facilitated by
appropriate chaperone molecules, including HSPs.
Table 4a Related
a adverse events reported among treated patients
(N¼72)
b
Number of patients with X1 related
adverse event (n(%)) 3 (4.2)
c
Adverse event n (%)
Blood and lymphatic system disorders
Anaemia 1 (1.4)
Leukocytosis 1 (1.4)
Eye disorders
Pupils unequal 1 (1.4)
General disorders and administration site conditions
Pyrexia 1 (1.4)
Metabolism and nutrition disorders
Metabolic acidosis 1 (1.4)
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort 1 (1.4)
Neoplasms benign, malignant, and unspecified
Paraneoplastic syndrome 1 (1.4)
Psychiatric disorders
Mental status changes 1 (1.4)
Renal and urinary disorders
Renal failure, acute 1 (1.4)
Respiratory, thoracic, and mediastinal disorders
Capillary leak syndrome 1 (1.4)
Dyspnoea 1 (1.4)
Respiratory failure 1 (1.4)
Vascular disorders
Flushing 1 (1.4)
aAdverse events assessed by the principal investigator as possibly, probably, or highly
probably related to HSPPC-96 administration.
bPatients are counted once within
each body system and preferred term.
cAll three patients were in the treatment
group that received only HSPPC-96.
Table 4b Severe related
a adverse events reported among treated
patients (N¼72)
b
Number of patients with X1 severe
related adverse event 1 (1.4)
c
Adverse event n (%)
Blood and lymphatic system disorders
Anaemia 1 (1.4)
Eye disorders
Pupils unequal 1 (1.4)
Metabolism and nutrition disorders
Metabolic acidosis 1 (1.4)
Neoplasms benign, malignant, and unspecified
Paraneoplastic syndrome 1 (1.4)
Psychiatric disorders
Mental status changes 1 (1.4)
Renal and urinary disorders
Renal failure, acute 1 (1.4)
Respiratory, thoracic, and mediastinal disorders
Capillary leak syndrome 1 (1.4)
Dyspnoea 1 (1.4)
Respiratory failure 1 (1.4)
aAdverse events assessed by the principal investigator as possibly, probably, or highly
probably related to HSPPC-96 administration and with NCI CTC severity or
investigator-determined severity of X3.
bPatients are counted once within each body
system and preferred term.
cThis patient was in the treatment group that received
HSPPC-96 only.
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antigens has been demonstrated to produce specific antitumour
immunity (Srivastava and Das, 1984; Palladino et al, 1987; Blachere
et al, 1993; Udono et al, 1994; Janetzki et al, 2000). The clinical trial
being reported in this paper was initiated in 1999 to help address
the issue of whether treating MRCC patients with the autologous
HSP90 product vitespen induces an antitumour response, and
whether subcutaneous outpatient IL-2 can convert vitespen
nonresponders into responders.
As seen in Table 1, evaluable individuals enrolled in this trial
had good performance status, with 31 (52%) exhibiting a baseline
performance status of 0. Forty-five patients had only 1 or 2 sites of
disease, and 48 had conventional type RCC. Twenty-five patients
had MSKCC good-risk prognosis after nephrectomy. Overall, this
group of individuals is expected to have a favourable outcome, and
to derive the greatest benefit from immunotherapy. It is important
to note, however, that all of these individuals presented with
metastatic disease upfront, and the time to first treatment was by
definition less than 1 year. Therefore, using the criteria published
in 2002, all patients had at least one negative risk factor. In
addition, it is apparent that a number of individuals had
sufficiently rapid disease progression to prevent nephrectomy or
vaccine administration. The absence of upfront systemic therapy
may be in part responsible for this rapid progression despite good
initial patient characteristics.
The vaccine was well tolerated in the vast majority of patients,
and this is consistent with the data accumulated in 771 patients
treated to date with Oncophage, where no other related
paraneoplastic synderomes were reported (Antigenics, Oncophage
Investigators Brochure). Time to progression from the first
vaccine administration for vaccine alone was 65 days (Table 2a).
It should be noted that it took a median of 38 days from the
enrolment date to the first vaccine treatment. Adding IL-2 did not
appear to have a significant impact on clinical outcome. Median
overall survival was 476 days (15.6 months), in keeping with the
reported overall survival for patients with good and intermediate
prognosis metastatic RCC. Although these data suggest that
patients were not harmed by receiving vitespen, the relatively
short TTP suggests minimal efficacy in the majority of individuals
on study.
The two individuals who ultimately achieved a complete
response showed signs of spontaneous regression after surgery
and before starting vitespen. It is possible that the complete
response seen in these agents was solely as a result of host factors
and was not due to the study drug. On the other hand, since a
number of individuals who show spontaneous regression ulti-
mately develop progressive disease without therapy, it is possible
that the study drug may have improved the durability of response
in these two individuals. It is important to note that one of these
patients had sarcomatoid histology, not traditionally associated
with immune responsiveness.
Several studies have been published in the past 10 years looking
at the efficacy of interferon (MRCRC Collaborators, 1999;
Pyrhonen et al, 1999), IL-2 (Yang et al, 2003b; McDermott et al,
2005; Tannir et al, 2006), and antivascular-targeted therapies
(Hainsworth et al, 2005; Escudier et al, 2007; Motzer et al, 2007) in
the treatment of patients with metastatic RCC. These treatments
demonstrate incremental gains in survival (MRCRC Collaborators,
1999; Pyrhonen et al, 1999), a small but consistent and durable
complete response rate (Yang et al, 2003b; McDermott et al, 2005)
or prolonged progression-free survival rates (Hainsworth et al,
2005; Escudier et al, 2007; Motzer et al, 2007). From a clinical
perspective, vitespen does not reach the threshold of therapy when
compared to these other agents.
It is not clear why vitespen failed to provide the anticipated
clinical benefit. Possibilities include an inherently weak immune
effect achieved by the proposed mechanism of action of vitespen,
or the inability to overcome T-regulatory cell inhibition. Other
possibilities include an inappropriate route or schedule of vaccine
administration. It is also possible that other forms of immune
costimulation or adjuvants are required to optimise vitespen’s
clinical effect. The combination of vitespen with anti-CTLA-4
blockade may also improve vitespen’s efficacy.
In conclusion, this study shows that vitespen is a relatively
ineffective agent in patients with metastatic RCC. If immune
modulation has occurred in these individuals, it is at a subclinical
level. Future investigations will require combination of vitespen
with immunostimulatory or targeted agents that may permit this
agent to reach the threshold of consistent clinical efficacy in the
metastatic setting.
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